21 October 2018 | News
The transaction is likely to complete by the end of this year.
Image credit- clpmag.com
Luminex has signed a definitive agreement to buy MilliporeSigma’s flow cytometry portfolio for $75 million.
This deal amount comprises around $69.9 million to be paid under a stock and asset purchase agreement and around $5.1million in committed inventory purchases.
The transaction is likely to complete by the end of this year and expected to contribute anywhere between $40 and $50 million in revenue to Luminex in 2019.
Luminex will be able to expand its current offering of flow-based detection systems, which is based on its innovative xMAP multiplexing technology. So far, over 15,000 xMAP systems have been sold across the world.